Q2 2024 Holdings
Filed 2024-08-14 | 63 holdings | $319.3M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Biohaven LTD(BHVN) | COM | G1110E107 | $17.0M | 490,000 | 5.3% |
| Alnylam Pharmaceuticals Inc(ALNY)Put | COM | 02043Q107 | $16.6M | 68,400 | 5.2% |
| Insmed Inc(INSM)Call | COM PAR $.01 | 457669307 | $13.4M | 200,000 | 4.2% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $13.2M | 300,000 | 4.1% |
| Soleno Therapeutics Inc(SLNO) | COM | 834203309 | $12.2M | 300,000 | 3.8% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $12.1M | 150,000 | 3.8% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $11.8M | 86,721 | 3.7% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $11.3M | 150,000 | 3.5% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $10.7M | 240,000 | 3.4% |
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $10.6M | 1,000,000 | 3.3% |
| Perspective Therapeutics Inc(CATX) | COM NEW | 46489V302 | $9.2M | 925,000 | 2.9% |
| TG Therapeutics Inc(TGTX) | COM | 88322Q108 | $8.9M | 500,000 | 2.8% |
| Sarepta Therapeutics Inc(SRPT) | COM | 803607100 | $8.7M | 55,000 | 2.7% |
| CG Oncology Inc(CGON) | COM | 156944100 | $8.2M | 260,000 | 2.6% |
| Corbus Pharmaceuticals Hldgs(CRBP) | COM NEW | 21833P301 | $7.9M | 175,000 | 2.5% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $7.6M | 587,708 | 2.4% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $7.2M | 350,000 | 2.3% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $6.9M | 260,000 | 2.1% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $6.4M | 235,000 | 2.0% |
| Phathom Pharmaceuticals Inc(PHAT) | COM | 71722W107 | $6.2M | 600,000 | 1.9% |
| Rezolute Inc(RZLT) | COM NEW | 76200L309 | $6.1M | 1,421,501 | 1.9% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $6.0M | 550,000 | 1.9% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $5.9M | 250,237 | 1.8% |
| Alnylam Pharmaceuticals Inc(ALNY) | COM | 02043Q107 | $5.5M | 22,500 | 1.7% |
| Apellis Pharmaceuticals Inc(APLS) | COM | 03753U106 | $5.2M | 135,000 | 1.6% |
| Viking Therapeutics Inc(VKTX) | COM | 92686J106 | $5.0M | 95,000 | 1.6% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $4.8M | 117,388 | 1.5% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $4.4M | 65,000 | 1.4% |
| Blueprint Medicines Corp(2L9) | COM | 09627Y109 | $4.3M | 40,000 | 1.4% |
| Savara Inc(SVRA) | COM | 805111101 | $4.2M | 1,050,876 | 1.3% |
| Tenaya Therapeutics Inc(TNYA) | COM | 87990A106 | $4.2M | 1,350,000 | 1.3% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $4.1M | 450,000 | 1.3% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $4.0M | 420,331 | 1.2% |
| Acadia Pharmaceuticals Inc(ACAD) | COM | 004225108 | $3.7M | 225,000 | 1.1% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $3.5M | 140,000 | 1.1% |
| Korro BIO Inc(KRRO) | COM | 500946108 | $3.4M | 100,000 | 1.1% |
| Nuvation BIO Inc(NUVB) | COM CL A | 67080N101 | $3.4M | 1,150,000 | 1.1% |
| Helix Acquisition Corp II | CL A ORD SHS | G4444H101 | $3.1M | 300,000 | 1.0% |
| Taysha Gene Therapies Inc(TSHA) | COM SHS | 877619106 | $2.8M | 1,250,000 | 0.9% |
| Cabaletta BIO Inc(CABA) | COM | 12674W109 | $2.8M | 370,899 | 0.9% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $2.5M | 70,000 | 0.8% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $2.1M | 50,000 | 0.7% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $2.0M | 75,000 | 0.6% |
| Regenxbio Inc(RGNX) | COM | 75901B107 | $2.0M | 170,000 | 0.6% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $1.8M | 33,200 | 0.6% |
| Elevation Oncology Inc | COM | 28623U101 | $1.6M | 600,000 | 0.5% |
| Krystal Biotech Inc(KRYS) | COM | 501147102 | $1.6M | 8,500 | 0.5% |
| Annexon Inc(ANNX) | COM | 03589W102 | $1.5M | 310,000 | 0.5% |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | $1.5M | 900,000 | 0.5% |
| Atyr Pharma Inc(ATYR) | COM NEW | 002120202 | $1.2M | 800,000 | 0.4% |